Active

Psoriatic Arthritis

Active

Ankylosing Spondylitis

Moderate to Severe

Juvenile Idiopathic Arthritis

Non-Infectious

Intermediate, Posterior and Panuveitis

Active

Psoriatic Arthritis

Moderate to Severe

Hidradenitis Suppurativa

Gastroenterology

Moderate to Severe

Crohn's Disease

Moderate to Severe

Pediatric Crohn's Disease

Moderate to Severe

Ulcerative Colitis

Moderate to Severe

Pediatric Ulcerative Colitis

Ophthalmology

Non-Infectious

Intermediate, Posterior and Panuveitis

Three women embrace while smiling

Resources for

Patient Access and support

YOUR SOURCE FOR SUPPORT

TO GET PATIENTS TIMELY ACCESS TO SKYRIZI

SKYRIZI® Complete enrollment icon

SKYRIZI COMPLETE ENROLLMENT

Ready to enroll your patient in Skyrizi Complete and start the process?

SKYRIZI® billing and coding icon

BILLING AND CODING

Clear guidance on billing and coding for SKYRIZI, including new NDC codes.

SKYRIZI® access icon

ACCESS AND REIMBURSEMENT

Forms and instructions to help patients with access and coverage.

 

SKYRIZI® pharmacy icon

SPECIALTY PHARMACIES

Contact details for specialty pharmacies

 

This information is for informational purposes only and is not intended to provide reimbursement or legal advice. The information presented here does not guarantee payment or coverage.

 

SKYRIZI® Complete enrollment icon

SKYRIZI COMPLETE ENROLLMENT

SKYRIZI COMPLETE ENROLLMENT AND PRESCRIPTION FORM

  • Download and fill out the Skyrizi Complete Enrollment and Prescription form with your patient
  • After submitting the form via fax, your patient will receive a call from a Nurse Ambassador*
  • You may also complete the Pharmacy Prescription Form and fax it to your patient's specialty pharmacy

ACCESS GUIDE

Get helpful access information for new SKYRIZI patients, including information on Access Specialists, Dosing, and Skyrizi Complete Enrollment and Prescription forms.

PRIOR AUTHORIZATION INSTRUCTIONS

Follow this helpful checklist to request coverage of SKYRIZI.

*Nurse Ambassadors are provided by AbbVie and do not provide medical advice or work under the direction of the prescribing healthcare professional (HCP). They are trained to direct patients to speak with their HCP about any treatment-related questions, including further referrals.

SKYRIZI® billing and coding icon

BILLING AND CODING

GUIDE TO BILLING AND CODING

Your guide to relevent codes (including commercial and Medicare) as well as helpful tips for completing forms.

NDC CODES

NEW SKYRIZI

Pen

150 mg/mL

0074-2100-01

Carton of 1

NEW SKYRIZI

Prefilled Syringe

150 mg/mL

0074-1050-01

Carton of 1

SKYRIZI

Prefilled Syringe

75 mg/0.83 mL

0074-2042-02

Carton of 2

With the approval and availibility of the single 150 mg/mL injection, SKYRIZI will be unavailable as two 75 mg/0.83 mL prefilled syringes by the end of 2021.

SKYRIZI® access icon

ACCESS AND REIMBURSEMENT FORMS

Along with support from Skyrizi Complete, you can use the forms here to help patients with access and coverage for SKYRIZI.

APPEALS LETTER SAMPLE

Appeal a denied claim for SKYRIZI.

TEMPLATE

FORMULARY EXCEPTION LETTER

Request a formulary exception to allow coverage for SKYRIZI.

TEMPLATE

HIPAA AUTHORIZATION

Allow patients to authorize the release of health information related to their treatment with SKYRIZI.

TEMPLATE

LETTER OF MEDICAL NECESSITY

Establish the medical necessity of SKYRIZI.

TEMPLATE

TIERED EXCEPTION LETTER

Request lower cost sharing for SKYRIZI as a preferred medication.

TEMPLATE

SKYRIZI® support

For support in person or over the phone, call your Access Specialist at 1.877.COMPLETE (1.877.266.7538)

SKYRIZI® pharmacy icon

SPECIALTY PHARMACIES

CONTACT DETAILS FOR SPECIALTY PHARMACIES

A complete list of specialty pharmacies that provide product-specific support for SKYRIZI.

Use these guides and best practices to help
get patients timely access to SKYRIZI

Computer screen Icon

SKYRIZI ONBOARDING

File Icon

ADDITIONAL RESOURCES

Video Icon

INJECTION SUPPPORT VIDEOS

Checkmark Icon

Injection Training Quick Tips

The resources on this page are provided for informational purposes only and are not intended as reimbursement or legal advice. The information presented here does not guarantee payment or coverage.

Computer screen Icon

SKYRIZI ONBOARDING

SKYRIZI COMPLETE ENROLLMENT AND PRESCRIPTION FORM

Download and fill out the Skyrizi Complete Enrollment and Prescription form with your patient. After submitting the form via fax, your patient will receive a call from a Nurse Ambassador.* You may also complete the Pharmacy Prescription Form and fax it to your patient's specialty pharmacy.

*Nurse Ambassadors are provided by AbbVie and do not provide medical advice or work under the direction of the prescribing healthcare professional (HCP). They are trained to direct patients to speak with their HCP about any treatment-related questions, including further referrals.

Resource dumped by HtmlRenderer

Resource path: /content/risahcp/en-us/support-and-resources/resources/resources-tab-2/jcr:content/contentpar/container_copy/containerparsys/container_240257867/containerparsys/container

Resource metadata: {sling.modificationTime=-1, sling.characterEncoding=null, sling.parameterMap={}, sling.contentType=null, sling.creationTime=-1, sling.contentLength=-1, sling.resolutionPath=/content/risahcp/en-us/support-and-resources/resources/resources-tab-2/jcr:content/contentpar/container_copy/containerparsys/container_240257867/containerparsys/container}

Resource type: nt:unstructured

Resource super type: -

Resource properties

jcr:primaryType: nt:unstructured

File Icon

ADDITIONAL RESOURCES

BENEFITS VERIFICATION CHART

Help patients confirm their insurance coverage and out-of-pocket costs.

INSURANCE COMPARISON

Simple steps to help patients choose their insurance coverage when it's time to pick a plan.

PATIENT BROCHURE

Prepare patients for treatment with SKYRIZI with information on plaque psoriasis, SKYRIZI efficacy, and more.

PASI SCORE CALCULATOR

Allows patients to enter the locations and severity of their symptoms and produce their current PASI score.

AAD RECOMMENDATIONS FOR TELEMEDICINE PREPAREDNESS

Tips for meeting with a dermatologist via phone or video chat from the American Academy of Dermatology Association.

Video Icon

INJECTION SUPPPORT VIDEOS

A patient-friendly video with instructions on the full process of injecting SKYRIZI.

150 mg/mL SKYRIZI PEN

150 mg/mL PREFILLED SYRINGE

INJECTION SUPPORT VIDEO - TWO 75 mg/0.83 mL PREFILLED SYRINGES

SKYRIZI will no longer be available in two 75 mg/0.83 mL prefilled syringes by the end of 2021. In the meantime, the Injection
Support Video is still available for reference.

Checkmark Icon

INJECTION TRAINING QUICK TIPS

A quick-tip guide for patients on how to inject, whether they have injected before or are new to it. 

150 mg/mL SKYRIZI PEN

150 mg/mL PREFILLED SYRINGE

looking for more resources?Offer enrollment to patients and submit forms
electronically with CompletePro.com

By registering through CompletePro.com, you can choose the
capabilities that are most relevant to you and your patients’ needs, such as:

Instant benefits verification:

  • Patient out-of-pocket costs
  • Any prior authorization requirements
  • Pharmacy options available to the patient
  • Patient eligibility for any drug discount from the pharmaceutical company

Online prescribing efficiencies:

  • Complete a Prior Authorization and send it directly to the insurer
  • Send a prescription directly to the patient's chosen pharmacy
  • Send Skyrizi Complete Savings Card to your patient's preferred specialty pharmacy (with or without a prescription)
  • Be notified via text, e-mail, or website in advance of patient's prior authorization expiration
  • Easily access each patient's prescription fill status

Stay up to date on the latest SKYRIZI news and information


Email Icon

ENROLL PATIENTS IN SKYRIZI COMPLETE

Resources for your patients

Checkmark Icon

Now available

The 150 mg/mL SKYRIZI Pen and
150 mg/mL prefilled syringe1

SKYRIZI® Pen and pre-filled syringe icon

Have you transitioned your patients?

Offer your patients the new 150 mg/mL
SKYRIZI Pen or 150 mg/mL prefilled syringe1

SKYRIZI® Pen and pre-filled syringe icon
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
Indication

SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Important Safety Information

Infection

SKYRIZI® (risankizumab-rzaa) may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, closely monitor and discontinue SKYRIZI until the infection resolves.

Tuberculosis (TB)

Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.

Administration of Vaccines

Avoid use of live vaccines in patients treated with SKYRIZI. Medications that interact with the immune system may increase the risk of infection following administration of live vaccines. Prior to initiating SKYRIZI, complete all age appropriate vaccinations according to current immunization guidelines.

Adverse Reactions

Most common (≥1%) adverse reactions associated with SKYRIZI include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.

SKYRIZI is available in a 150 mg/mL prefilled syringe and pen.

Please see Full Prescribing Information.

US-SKZD-210127

REFERENCE

  1. SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc.
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
Infection SKYRIZI® may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated. Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
Infection SKYRIZI® may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
Infection SKYRIZI® may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated. Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
Infection SKYRIZI® may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
Indication

SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Important Safety Information

Infection

SKYRIZI® (risankizumab-rzaa) may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, closely monitor and discontinue SKYRIZI until the infection resolves.

Tuberculosis (TB)

Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.

Administration of Vaccines

Avoid use of live vaccines in patients treated with SKYRIZI. Medications that interact with the immune system may increase the risk of infection following administration of live vaccines. Prior to initiating SKYRIZI, complete all age appropriate vaccinations according to current immunization guidelines.

Adverse Reactions

Most common (≥1%) adverse reactions associated with SKYRIZI include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.

SKYRIZI is available in a 150 mg/mL prefilled syringe and pen.

Please see Full Prescribing Information.

US-SKZD-210127